论文部分内容阅读
目的探讨多西紫杉醇、紫杉醇联合顺铂、5-氟尿嘧啶(5-FU)治疗胃癌临床疗效。方法 2008年3月至2011年3月收治的符合入选标准晚期胃癌患者96例,依据治疗方法不同分为多西紫杉醇组50例,紫杉醇组46例;观察两组临床疗效及不良反应。结果两组患者均完成2个周期化疗,按照按WHO实体瘤疗效评价标准[2]进行评价,多西紫杉醇组总有效24例(48.00%),紫杉醇组总有效46例(45.65%),经统计学分析,差异无统计学意义(P>0.05)。结论在晚期胃癌化疗中应用紫杉醇、多西紫杉醇联合顺铂、5-FU方案均能够取得较为良好的临床效果,安全性相差不大,可以作为患者依据经济条件选取方案。
Objective To investigate the clinical efficacy of docetaxel, paclitaxel combined with cisplatin and 5-fluorouracil (5-FU) in the treatment of gastric cancer. Methods A total of 96 patients with advanced gastric cancer admitted to our hospital from March 2008 to March 2011 were divided into docetaxel group (n = 50) and paclitaxel group (n = 46) according to different treatment methods. Clinical efficacy and adverse reactions were observed in both groups. Results Two cycles of chemotherapy were completed in both groups. According to the WHO Evaluation Criteria for Solid Tumors (2), the total effective rate was 24 (48.00%) in docetaxel group and 46 (45.65%) in paclitaxel group. Statistical analysis, the difference was not statistically significant (P> 0.05). Conclusions The application of paclitaxel, docetaxel combined with cisplatin and 5-FU in advanced gastric cancer chemotherapy can achieve good clinical results with little difference in safety, which can be used as the basis for selecting patients according to economic conditions.